GALECTIN THERAPEUTICS INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
GALECTIN THERAPEUTICS INC. (GALT) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-31
- GALECTIN THERAPEUTICS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.50%, a 87.50% decline from fiscal 2024.
- GALECTIN THERAPEUTICS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 4.00%.
- GALECTIN THERAPEUTICS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -2.30%, a 264.29% decline from fiscal 2022.
- GALECTIN THERAPEUTICS INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 1.40%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.50% 10-K · filed 2026-03-31 | |
| 2024-12-31 | 4.00% 10-K · filed 2026-03-31 | |
| 2023-12-31 | -2.30% 10-K · filed 2025-03-31 | |
| 2022-12-31 | 1.40% 10-K · filed 2024-03-29 | -1.40% 10-K · filed 2023-03-30 |
| 2021-12-31 | -0.10% 10-K · filed 2023-03-30 | |
| 2020-12-31 | -2.20% 10-K · filed 2022-03-31 | 2.20% 10-K · filed 2021-03-31 |
| 2019-12-31 | 4.20% 10-K · filed 2021-03-31 | |
| 2018-12-31 | -1.10% 10-K · filed 2020-03-16 | |
| 2017-12-31 | 4.90% 10-K · filed 2019-03-06 | |
| 2015-12-31 | -1.60% 10-K · filed 2017-03-28 | 0.90% 10-K · filed 2016-03-15 |
| 2014-12-31 | -1.40% 10-K · filed 2017-03-28 | 1.40% 10-K · filed 2015-03-18 |
| 2013-12-31 | 1.80% 10-K · filed 2016-03-15 | |
| 2012-12-31 | 3.30% 10-K · filed 2015-03-18 | |
| 2011-12-31 | 3.40% 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |